Kookjeon Pharmaceutical Co., Ltd. (KOSDAQ:307750)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,957.00
-78.00 (-3.83%)
At close: Jul 28, 2026

Kookjeon Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
127,427131,039136,468121,998103,71185,354
Revenue Growth
-5.92%-3.98%11.86%17.63%21.51%-
Gross Profit
19,43618,46621,87425,27719,51517,946
Operating Income
-14.25-2,564366.716,5093,4886,109
Net Income
-7,849-4,2991,7364,8248,9484,038
Earnings Per Share
-156.21-86.2235.0098.3111.3591.00
EPS Growth
---64.40%766.11%-87.53%-

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
30,38630,54946,82464,83394,97139,259
Total Debt
40,18945,90265,31278,78059,3397,852
Net Cash (Debt)
-9,803-15,354-18,488-13,94735,63231,407
Net Cash Growth
----13.45%-
Net Cash Per Share
-195.09-307.93-372.69-284.24695.44712.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
8,44610,6089,967-345.45-6,0193,042
Capital Expenditures
-3,919-3,114-7,867-43,923-23,285-10,409
Free Cash Flow
4,5277,4942,100-44,269-29,304-7,367
Free Cash Flow Growth
52.86%256.91%----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
15.25%14.09%16.03%20.72%18.82%21.02%
Operating Margin
-0.01%-1.96%0.27%5.33%3.36%7.16%
Pretax Margin
-7.45%-4.32%0.64%1.42%10.69%5.96%
Profit Margin
-6.16%-3.28%1.27%3.95%8.63%4.73%
FCF Margin
3.55%5.72%1.54%-36.29%-28.26%-8.63%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--99.3463.4736.30133.06
P/FCF Ratio
23.3422.5382.14---
PS Ratio
0.831.291.262.513.136.30